Form 4 · Filed May 13, 2026, 09:00 PM UTC
IOVA/IOVANCE BIOTHERAPEUTICS, INC.
Kirby Daniel Gordon — Chief Commercial Officer
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
3 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 11, 2026 | M | other | 10,000 | $0 | — | 149,381 |
| May 11, 2026 | F | other | 2,435 | $4 | $9,010 | 146,946 |
| May 11, 2026 | M | other | 10,000 | — | — | 70,004 |
Source: SEC EDGAR raw filing ↗ · Accession 0001104659-26-060356